Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07552077 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

Study acronym: LOTU
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
Trial Details
NCT Number NCT07552077
Lead Sponsor Palvella Therapeutics, Inc.
Conditions
(from sponsor)		 Angiokeratomas
Related terms Angiokeratoma
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov